Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference session hosted by Leerink ...

Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDTCompany ParticipantsJasper Van GrunsvenPeter Griffith - Executive ...

The new TrumpRx website is now live, and a number of medications have seen a sizeable decrease in cost. Here are some of the medicines that have seen the largest drops in cost since the website went ...

Danish experts now fear that more pharma companies will withdraw medicines from Denmark to avoid being penalised in the US market ...

Wall Street is drawing fresh lines across the large-cap biopharma landscape, initiating coverage on two stocks and maintaining an overweight rating on another.

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

2026年3月11日周三,安进(NASDAQ:AMGN)在2026年Leerink全球医疗保健会议上发表演讲,阐述了稳健的战略展望,同时也承认了潜在挑战。该公司强调了2025年在关键产品和创新疗法推动下的强劲表现,但也指出保险周期和仿制药竞争对近期增长的影响。 MariTide每月或每季度给药 ...

Investing.com - 杰富瑞(Jefferies)首次覆盖安进公司(Amgen Inc.)(NASDAQ:AMGN),给予持有评级,并将目标价设定为$350,该报告于周一发布。 该公司表示,安进股票在当前水平上估值合理。杰富瑞指出,该公司面临99亿美元的专利到期缺口,但可以通过基础业务增长来抵消。 分析师表示,从当前水平上涨取决于心脏代谢管线的乐观情况,包括MariTide和olpasi ...